Tezosentan je neselektivni ETA u ETB receptorski antagonist.[5] On deluje kao vazodilatator i bio je dizajniran za terapiju pacijenata sa akutnom srčanom insuficijencijom. Nedavne studije su međutim pokazale da tezosentan ne poboljšava dispneju niti redukuje rizik od kardiovakularnih problema.[6]
Tezosentan
|
(IUPAC) ime
|
N-[6-(2-Hidroksietoksi)-5-(2-metoksifenoksi)-2-[2-(2H-tetrazol-5-il)piridin-4-il]pirimidin-4-il]-5-propan-2-ilpiridin-2-sulfonamid
|
Klinički podaci
|
Identifikatori
|
ATC kod
|
nije dodeljen
|
PubChem[1][2]
|
151174
|
ChemSpider[3]
|
133242
|
ChEMBL[4]
|
CHEMBL61780 Y
|
Hemijski podaci
|
Formula
|
C27H27N9O6S
|
Mol. masa
|
605,624
|
SMILES
|
eMolekuli & PubHem
|
InChI |
InChI=1S/C27H27N9O6S/c1-16(2)18-8-9-22(29-15-18)43(38,39)34-26-23(42-21-7-5-4-6-20(21)40-3)27(41-13-12-37)31-24(30-26)17-10-11-28-19(14-17)25-32-35-36-33-25/h4-11,14-16,37H,12-13H2,1-3H3,(H,30,31,34)(H,32,33,35,36) Y Key: TUYWTLTWNJOZNY-UHFFFAOYSA-N Y |
|
Farmakoinformacioni podaci
|
Trudnoća
|
?
|
Pravni status
|
|
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑ Urbanowicz, W; Sogni, P, Moreau, R, Tazi, K A, Barriere, E, Poirel, O, Martin, A, Guimont, M C, Cazals-Hatem, D, Lebrec, D (2004). „Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats”. Gut (BMJ Publishing Group Ltd & British Society of Gastroenterology) 53 (12): 1844–1849. DOI:10.1136/gut.2003.036517. PMC 1774327. PMID 15542526.
- ↑ „Tezosentan does not appear to improve symptoms for patients with acute heart failure”. Medical Studies/Trials. news-medical.net. 7-Nov-2007. Pristupljeno 24. 11. 2007.
Spoljašnje veze
uredi